Andrew joined SV in 2022 as an Associate on the Healthcare Growth Team, was promoted to Senior Associate in 2024, and to Vice President in 2025.
Prior to joining SV, Andrew was a member of Thermo Fisher Scientific’s Corporate Development team, focused on mergers and acquisitions of healthcare and life science companies. He executed two M&A transactions with an aggregate value of $550 million.
Outside of SV, Andrew enjoys exploring Boston, golfing, skiing, and spending time with family and friends.
Academic Credentials
B.S., Business Administration: Finance, University of New Hampshire
